Nexien BioPharma Reports Improved Losses Amid Ongoing Financial Struggles and No Revenue Generation

Nexien BioPharma, Inc. (PINK: NXEN) has reported its financial results for the period ending March 31, 2025, revealing critical insights into its operations and financial health.

Key Financial Highlights:

• Net Loss: The company reported a net loss of $30,092 for Q3 2025 compared to a loss of $53,163 for Q3 2024, reflecting a positive decrease of $23,071.
• Overall Loss: For the nine-month period ending March 31, 2025, the net loss was $101,568, down from $152,599 in the same period last year.
• Operating Expenses: Total operating expenses decreased to $14,300 from $15,947 in Q3 2024, with general and administrative costs reducing from $9,282 to $4,960, mainly due to lower compensation-related costs.
• Interest Expense: Interest expenses increased slightly from $10,238 to $11,429 in Q3 2025, influenced by non-interest-bearing advances from an officer.
• Cash Position: Cash at March 31, 2025, was $8,285, up from $4,183 as of June 30, 2024, indicating a positive cash flow trend.
• Working Capital Deficit: The company’s working capital deficit grew to $450,516 from $361,249 over nine months, indicating ongoing financial strain.
• Outstanding Notes: The company has convertible notes totaling $70,000 to its CEO and shareholder, alongside $207,120 owed to Quick Capital.

Negative Aspects to Consider:

• No revenue was generated during the reported period, signaling challenges in the business model.
• The operating loss since inception stands at $11,636,041, highlighting ongoing financial pressure.
• The ability to continue as a going concern is fraught with uncertainty as substantial capital is needed to maintain operations and pursue drug development ventures.
• The earnings per share remained at $0.000 for both periods, indicating minimal progress towards profitability.

Outlook: Nexien BioPharma continues to face substantial hurdles in achieving operational stability and generating revenue. With plans to pursue additional funding, the future of the company hinges on successful fundraising and the execution of its drug development projects.